The FUSION GENOMICS Teams
FUSION GENOMICS is made up of passionate and skilled individuals with decades of experience in genomics, research, IT, and business development.
Dr Qadir’s training is in genetics and molecular biology. Dr Qadir has over 17 years of research experience. The last ten were at the British Columbia Cancer Agency where he worked with world-renowned experts in genomics and drug development. Dr Qadir is the co-inventor of the CHILDSeq-Sarcoma assay and CHILDDecode (part of FUSIONCloud™). Dr Qadir oversees all the scientific aspects of research and development efforts at FUSION GENOMICS and also serves as the interface for all collaborators.
Mr Greg Stazyk has over 20 years of experience in senior positions in the IT industry, including senior manager at PMC-Sierra Inc. where he was responsible for its global computer systems operation. Mr. Stazyk was the IT lead for one of Canada’s largest bioinformatics computing platforms at the BC Cancer Agency’s Genome Sciences Centre. Here, he oversaw the expansion of their computing infrastructure from a few dozen core-machines to over 10,000 in the core cluster and over 7 Petabyte of redundant storage in a CAP/CLIA certified environment. Mr Stazyk brings insight and expertise in IT project management, especially in areas of business fault tolerance and secure storage systems, which are critical for fulfilling FUSION GENOMICS’ cloud computing needs.
Mr Jameel has over 25 years of experience in transaction support, PE & VC investments and fund raising. He has participated in over US$ 1 billion of transactions and has board level experience on a number of companies. Mr Jameel has advised startups in the fields of media, technology and logistics. He is a CFA charter holder and holds a Masters degree in accounting and finance from the London School of Economics and Political Sciences.
Dr Sobel has over 20 years experience in research, grant writing and development, communication and project management. After spending seven years in prostate cancer research as an Associate Scientist at the BC Cancer Agency and the Genome Sciences Centre (GSC), he left the “bench” to work at the Fraser Valley Cancer Centre as a Research Development Officer, and returned to the GSC as a project manager. As a Research Development Facilitator for four years, Dr Sobel was an integral member of the Research and Technology Development Office team at the Child & Family Research Institute, which helps bring in $20 million dollars of peer-reviewed research funding each year for institute investigators.
Kian-Guan Lim is a serial entrepreneur who has helped a number of biotechnology and health-related companies grow to maturity. His areas of expertise include leading teams, developing products, creating distribution networks, and establishing key partnerships.
One of FUSION GENOMICS’ strongest supporters, he is deeply involved in guiding the company’s strategies. In addition, he has secured relationships with many of Fusion’s investors, opening opportunities in Singapore, Hong Kong, China, and Taiwan.
Dr. Sorensen uses a combination of genetic and biochemical approaches to identify and discover proteins that are specifically altered in childhood cancers and adult breast tumours. His initial discoveries have been translated by FUSION GENOMICS into new diagnostic tests for specific tumours, and have advanced our understanding of how the involved proteins transmit signals that cause cells to become cancerous. Dr. Sorensen is also the Chair of the Translational Research Committee of the Children’s Oncology Group (COG), the largest pediatric oncology clinical trials network in the world.
Dr Anthony is a Molecular Biologist who specializes in molecular diagnostics. He has extensive experience in development of molecular tests for bacterial drug resistance, bacterial and fungal typing, and microarray based diagnostics.
Between April 1996 and May 2001 he was employed by King’s College London, UK, on the epidemiology and rapid detection of bacterial infection with a focus on the laboratory diagnosis of hospital acquired infection particularly MRSA. Currently, his work as Research Coordinator for the tuberculosis research group in KIT Biomedical Research is directed towards improving tuberculosis diagnostics, understanding the acquisition of drug resistance in Mycobacterium tuberculosis and adapting and simplifying multiplex assays methods so they can be more widely applied for diagnostic use.
Dr Underhill is a Professor in the Department of Cellular and Physiological Sciences at the University of British Columbia. He completed his PhD at Western University (1991) and carried out post-doctoral training at Duke University (1991-95) where he studied the function of the retinoid signaling in limb development. Following this, he became an Assistant Professor at Western University (1996) where his group described fundamental roles for retinoid signaling in regulating mesenchymal cell differentiation. In 2004, he joined UBC and his interests expanded to include investigating how mesenchymal progenitors support tissue regeneration and tumorigenesis. Dr Underhill served as the Scientific Director at the Centre for Drug Research and Development from 2013-2015, a not-for-profit independent organization promoting and facilitating commercialization of academia-based discoveries. From 2001-2011 he held salary awards from the Canadian Institutes of Health and the Arthritis Society.
Dr Chopra has over 15 years of research experience and over four years management experience. Dr Chopra obtained his PhD under the mentorship of Dr. Michael Hayden, a world renowned geneticist at the University of British Columbia, and further training under Dr Robert Holt, a leading expert in DNA sequencing at the Genome Sciences Centre. Dr Chopra also holds an MBA from Simon Fraser University. For the past several years, he has managed large-scale pre-commercialization genomics projects for Genome British Columbia. Dr Chopra has a keen interest in genomics-driven in vitro diagnostics and their regulatory landscape.
Mr Kwok is a graduate of the molecular biology and biochemistry program at Simon Fraser University and trained at the BC Cancer Agency’s Genome Sciences Centre. Mr.Kwok has 10 years of experience in molecular biology and genomic technologies including leading edge Next Generation Sequencing (NGS). Mr. Kwok worked at the Koninklijk Instituut voor de Tropen (KIT), also known as The Royal Tropical Institute in the Netherlands, where he was actively involved in developing molecular diagnostic assays for the identification of drug-resistant tuberculosis. Mr. Kwok has worked in combinatorial drug screening and led the development of the CHILDSeq-Sarcoma assay. He is responsible for the development, testing, and production of Fusion’s new assays.
Dr Alamouti received her PhD and MSc in Microbiology from the University of British Columbia. Subsequent work involved research on fungal pathogens destroying pine forests in Western North America which resulted in 7 peer-reviewed publications. This work included using NGS to assemble fungal genomes to identify species and variants and required data mining and computational approaches. Dr Alamouti’s last position studied various cancer cohorts to elucidate tumor evolution and related somatic mutations for developing assays to detect the presence of tumor cells and key driver mutations in patient blood streams.
Dan Fornika has been involved in genomics research in the Vancouver area for over 10 years. He completed a BSc at Simon Fraser University in 2006, and a MSc at the University of British Columbia in 2012. As a Co-Operative Education student, Dan worked several terms at Defense R&D Canada – Suffield, developing serum-screening assays for anti-Anthrax antibodies. His work shifted to human genomics during his time at Canada’s Michael Smith Genome Sciences Centre, where he focused on understanding the mitochondrial genomics of the human aging process. Subsequent work has focused on both cancer genomics and software development. Dan’s dual skill sets in computational biology and laboratory science enable him to transition smoothly between the lab bench and the bioinformatics workstation.
His responsibilities at Fusion Genomics include assay development and optimization, as well as analysis pipeline development.
Mr Zhan graduated from the University of British Columbia with a BSc in Genetics (Honours). He has already published 13 scientific articles (three as first or co- first author) in well-respected journals, including Science and the American Journal of Human Genetics. He has proven expertise in computational biology, especially in the analysis of next-generation sequencing data, and in the development of bioinformatics and statistical methodologies that have been published in peer-reviewed articles. Mr Zhan’s goal is to develop novel bioinformatic methods that can solve ground-breaking biological problems.
Mr Lefebvre is a graduate of the bioinformatics program at University of Toronto and University of British Columbia. During his graduate studies at the British Columbia Cancer Agency, Calvin applied genomic analysis to a wide variety of cancer types.
His current research interest is applying machine learning techniques to relatively unexplored areas.
Mr Zhao received his Masters in Mathematics from the University of Waterloo in 2015. As an undergraduate, he majored in both computer science and biology. As an intern at McGill University, he designed and implemented algorithms for studying tuberculosis transmission. He brainstormed, designed, implemented, and documented 7 test suites that automate UI testing experience with Used R, Mixed Model, and Nonparametric Statistics.
HanJo Jang graduated from Simon Fraser University, where he majored in computer science.
Mr Jang is a part of Fusion Genomics’ bioinformatics team, developing and testing Fusion Cloud.